Cholesterol-Lowering Therapy

Reveals the results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This book highlights historical studies of dietary trials designed to reduce CHD; covers tests of HMG COA reductase inhibitors for patients with and without CHD; and more. It is for cardiologists, pharmacologists, and others.
Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States.
This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations.
Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants.
Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence
highlights historical studies of dietary trials designed to reduce CHD

covers tests of HMG CoA reductase inhibitors for patients with and without CHD

illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking

explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors

reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol

and more!
Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.